Azacitidine and decitabine for myelodysplastic syndrome - horizon scanning review
National Horizon Scanning Centre
Record ID 32004000142
English
Authors' objectives:
This study aims to assess the effectiveness of azacitidine and decitabine for myelodysplastic syndrome.
Authors' recommendations:
Azacitidine (5-azacitidine) and decitabine (Dacogen(TM), 5-aza-2'-deoxycitidine) are DNA methyltransferase inhibitors that reduce DNA synthesis and the growth of tumour cells. Both azacitidine and decitabine are in phase III clinical trials for myelodysplastic syndrome (MDS). A randomised controlled phase III of azacitidine in 191 patients with MDS has been published; responses occurred in 60% of patients on azacitidine compared with 5% receiving supportive care (p<0.001).
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.pcpoh.bham.ac.uk/publichealth/horizon/
Year Published:
2003
URL for published report:
n/a
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Azacitidine
- Hematologic Diseases
- Myelodysplastic Syndromes
- Decitabine
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.